AbbVie Bets $10.9BThat Eczema Patients Want a Shot Four Times a Year, Not Twenty-Six (Genius)
Low commitment? Say less.
There is no part of your life you want to deal with every two weeks. Not the gym (at least for me), not your in-laws, and definitely not a needle. On Monday, AbbVie bet $10.9 billion that eczema patients feel exactly the same way.
That’s a straight cash home check for Apogee Therapeutics, AbbVie's biggest buyout in over five years. $135.11 a share, a 49.49% premium, and Apogee stock is mooning because of it. Why the splurge? Because Humira is dying, that’s why. The drug that built AbbVie collapsed 38.6% last quarter to $688 million, a long way down from its $21 billion peak, and the patents on its heirs, Skyrizi and Rinvoq (currently printing), are already visible from here. So AbbVie did what it's done all decade and went deepthroating biotechs "building new growth drivers."
Apogee follows the $10.1 billion ImmunoGen deal and the Cerevel pickup. What $10.9 billion actually buys is zumilokibart, a name that sounds like it lost a fight with a bag of Scrabble tiles. I can't pronounce it either. Jokes aside, Zumu is an IL-13 inhibitor for moderate-to-severe atopic dermatitis (read: eczema) and asthma, and in trials roughly two-thirds of patients hit serious skin clearing by week 16.
That said, here’s the entire bet. Sanofi and Regeneron's Dupixent owns this market, $10 billion in sales and 1.4 million patients. But Dupixent is the clingy one. It wants to see you every two weeks, indefinitely. Zumilokibart is being studied as a shot you take once every three to six months. Which means, AbbVie is wagering eleven figures that patients would rather get stuck four times a year than twenty-six. Genius.
Of course, Wall Street in all its glory saw this coming. Apogee had "long been viewed as a potential takeover target," per RBC, specifically because of that dosing gap, and the eczema market keeps growing. AbbVie's immunology arm already throws off more than $30 billion a year. So bolting a lower-maintenance Dupixent rival onto that pile is the kind of move that sells itself. However, there is a catch. AbbVie says the deal won't add a cent to earnings until 2032, which is six years of babysitting a drug that still has to clear trials and regulators before it sells a single dose. It should close in Q3.
Moral of the story? The trade is 100% “bet on laziness”. Nobody wants to commit to anything more than they absolutely have to. And AbbVie is going full-send on that thesis. Place your bets accordingly, friends. Until next time…

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.